ELEVIDYS

Sarepta Therapeutics presented new findings at the 2026 World Muscle Society Annual Congress showing that ELEVIDYS (delandistrogene moxeparvovec) is safe and delivers clinically meaningful functional benefit in older ambulatory patients with Duchenne muscular dystrophy. The data extend the gene therapy's evidence base beyond younger patient groups, a question that has long been debated by clinicians and regulators in the Duchenne community.